Since the second edition was released in 2011 the Good Participatory Practice guidelines have been the subject of several landmark peer reviewed articles. As the guidelines, and stakeholder engagement in HIV more broadly, continue to be highlighted in peer reviewed journals, we will collect those articles and make them available.
Below is a selection of peer-reviewed articles featuring the challenges and opportunities of implementing GPP throughout a research trial. If you would like additional resources please visit our GPP tools page or contact us at email@example.com.
Key Articles Featuring GPP
- Developing a Framework for Evaluating Ethical Outcomes of Good Participatory Practices in TB Clinical Drug Trials
- Improving Ethical and Participatory Practice for Marginalized Populations in Biomedical HIV Prevention Trials: Lessons from Thailand
- Implementing Good Participatory Practice Guidelines in the FEM-PrEP Preexposure Prophylaxis Trial for HIV Prevention among African Women: A focus on local stakeholder involvement
- Towards a Science of Community Stakeholder Engagement in Biomedical HIV Prevention Trials: An embedded four country case study
Key Articles Referencing GPP
- Consent and Community Engagement in Diverse Research Contexts: Reviewing and developing research and practice
- Fostering Community Understanding of Sufficient Benefit and Early Stopping for a Phase 2B HIV Prevention Clinical Trial in Africa
- How Good Is ‘Good Enough’? The Case for Varying Standards of Evidence According to Need for New Interventions in HIV Prevention
- Investing in the Future: Lessons learnt from communicating the results of HSV/HIV intervention trials in South Africa
- Public/Community Engagement in Health Research with Men Who have Sex with Men in sub-Saharan Africa: Challenges and opportunities
- Successful Discontinuation of the Placebo Arm and Provision of an Effective HIV Prevention Product After a Positive Interim Efficacy Result: The Partners PrEP Study Experience
- Testing the Waters: Ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial